FDA Highlights by Bruce Sylvester – Bazedoxifene, approved in Europe to treat osteoporosis, appears to stop the growth of breast cancer cells, even in therapy-resistant tumors, researchers from… read more.
Trend toward more cancers and more deaths among heart failure patients. Heart failure patients are surviving more often with the heart condition but they are increasingly more likely… read more.
Men with chronic pain and opioid-induced androgen deficiency may find some pain relief with testosterone replacement therapy, a small trial suggested.
In recent years, there has been an adjustment in the scientific thinking about the utility of screening men for prostate cancer using prostate-specific antigen (PSA).
by Elizabeth C. Smyth, MB, BCh, MSc, and David Cunningham, MD, FRCP, FMedSci – In 2000, in order to optimise service provision for patients with cancer, 34 “Cancer… read more.
CHICAGO – Five pivotal studies were released today ahead of the plenary session of the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
by Jamie Von Roenn, MD, and Charles von Gunten, MD, PhD – The call to integrate palliative care practices and principles into comprehensive cancer care, not as something… read more.
The American Society of Clinical Oncology (ASCO) kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US… read more.
CHICAGO – The American Society of Clinical Oncology (ASCO) has completed the first phase in developing several sets of interoperability standards for cancer care data and overcoming the… read more.
CHICAGO – New advances against melanoma, ovarian cancer, and colorectal cancer care were presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)…. read more.
New research analysing breast cancer mortality data spanning almost 40 years concludes that breast cancer screening does not yet show an effect on mortality statistics. The research, published… read more.
by Bruce Sylvester – Patients with an advanced kind of lung cancer and a dysfunctional ALK gene have achieved better outcomes with the targeted investigative therapy crizotinib rather… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
